Voyager Therapeutics Inc $ 11.76 -0.06 (-0.51%)
Volume:
291,160
Avg Vol (1m):
382,786
Market Cap $:
435.97 Mil
Enterprise Value $:
163.38 Mil
P/E (TTM):
0.00
P/B:
4.00
Financial Strength |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 8.83 | ||
| Equity-to-Asset | 0.29 | ||
| Debt-to-Equity | 0.32 | ||
| Debt-to-EBITDA | -0.6 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 0.38 | ||
| Beneish M-Score | 0.85 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -82.84 | ||
| Net Margin % | -72.64 | ||
| ROE % | -60.96 | ||
| ROA % | -17.27 | ||
| ROC (Joel Greenblatt) % | -193.39 | ||
| 3-Year Revenue Growth Rate | -61.4 | ||
| 3-Year EBITDA Growth Rate | 16 | ||
| 3-Year EPS without NRI Growth Rate | 33 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Owner-Earnings | 12.98 | ||
| PB Ratio | 4 | ||
| PS Ratio | 5.93 | ||
| Price-to-Free-Cash-Flow | 8.13 | ||
| Price-to-Operating-Cash-Flow | 7.46 | ||
| EV-to-EBIT | -2.68 | ||
| EV-to-EBITDA | -2.81 | ||
| EV-to-Revenue | 2.24 | ||
| Current Ratio | 4.09 | ||
| Quick Ratio | 4.09 | ||
| Days Sales Outstanding | 58.09 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4 | ||
| Price-to-Median-PS-Value | 0.22 | ||
| Earnings Yield (Greenblatt) % | -37.4 |